Outcomes of Surgical Management of Retroperitoneal Paragangliomas: A Single Centre Experience
Indian Journal of Surgical Oncology · 2026-04 · 17 (4) · 813-818
DOI: 10.1007/s13193-026-02538-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Surgical Oncology, online erschienen am 17.03.2026. Verfasst von Yalini Devi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Dr Ernest Borges Rd., Parel East, Parel, Mumbai, Maharashtra…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Retroperitoneal paragangliomas (RP-PGLs) are rare extra-adrenal neuroendocrine tumors representing ~ 1-3% of retroperitoneal masses. They may secrete catecholamines, causing hypertension and life-threatening complications if untreated. Surgical resection is the mainstay of therapy, yet data-particularly from the Indian subcontinent-are scarce. To evaluate clinical presentation, diagnostic workup, perioperative management and long-term outcomes of RP-PGL resections at a tertiary oncology center. A retrospective analysis of 30 patients who underwent RP-PGL resection from 2005 to 2023 was done. Preoperative evaluation was based on standard institutional protocols after a multidisciplinary discussion. Data collected included operative time, blood loss, histopathology (tumor size, stage, margins, SDH/MEN mutations) and Clavien-Dindo morbidity. Overall survival (OS) and disease-free survival (DFS) were estimated via Kaplan-Meier analysis. Median age was 44 years (range 22-66); 40% were male. Presentations: pain (56.7%), incidental mass (23.3%), classical symptoms (6.7%). Half had secretory tumors; 40% of these exhibited uncontrolled hypertensions. R0 resection was achieved in 73.3%, including 13.3% multivisceral/vascular resections. SDH and MEN mutations were found 16.7%, and 3.3% respectively. Postoperative morbidity ≥Clavien-Dindo IIIa occurred in 16.7%, with no 90-day mortality. At a median follow-up of the 36.9 months (95% C.I: 10.9 to 62.8 months), median OS and DFS were not reached and the 3-year Overall survival (OS) and 3-year disease free survival (DFS) was 95.5% (91.1 to 99.9%) and 89.1% (81.6 to 96.6%) respectively. Three recurrences occurred; two responded to peptide receptor radionuclide therapy. Surgical management of RP-PGLs is safe and achieves excellent long-term survival. A standardized diagnostic algorithm, multidisciplinary perioperative optimization and readiness for complex resections are key to favorable outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Dr Ernest Borges Rd., Parel East, Parel, Mumbai, Maharashtra 400012 India.
- Department of Pathology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
- Department of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
ORCID-Profile: Shraddha Patkar
Zitieren
APA
Devi, Y., Shah, T. M., Kazi, M., Patkar, S., Kaushal, R. K., Gala, K., & Goel, M. (2026). Outcomes of Surgical Management of Retroperitoneal Paragangliomas: A Single Centre Experience. Indian Journal of Surgical Oncology, 17(4), 813-818. https://doi.org/10.1007/s13193-026-02538-2
Vancouver
Devi Y, Shah TM, Kazi M, Patkar S, Kaushal RK, Gala K, et al. Outcomes of Surgical Management of Retroperitoneal Paragangliomas: A Single Centre Experience. Indian Journal of Surgical Oncology. 2026;17(4):813-818. doi:10.1007/s13193-026-02538-2
BibTeX
@article{Devi2026,
author = {Devi, Yalini and Shah, Tanvi M and Kazi, Mufaddal and Patkar, Shraddha and Kaushal, Rajiv Kumar and Gala, Kunal and Goel, Mahesh},
title = {Outcomes of Surgical Management of Retroperitoneal Paragangliomas: A Single Centre Experience},
journal = {Indian Journal of Surgical Oncology},
year = {2026},
volume = {17},
number = {4},
pages = {813--818},
doi = {10.1007/s13193-026-02538-2}
}
EUVIMED